Aitchison Lab

Lab Team

Chris Carter, MD, PhD

Fellow, visiting scientist 

Dr. Chris Carter is a fellow in the University of Washington Infectious Disease Training Program and a visiting scientist at the Center for Global Infectious Disease Research. He completed his graduate and medical training at the University of Michigan, where his research focused on HIV latency. In the Aitchison Lab, Carter is employing traditional and systems-based interactomics approaches to study virus-host interactions.

Fergal Duffy, PhD


Dr. Fergal Duffy is a computational biologist specializing in machine learning and structural modelling. He applies these approaches to help predict, diagnose and understand the human immune response to infectious diseases, especially TB and malaria. Along with this work, he is integrating different experimental approaches to determine the structure of protein complexes involved in fundamental transcriptional processes.

Thurston Herricks, PhD

Research scientist IV

Thurston HerricksDr. Thurston Herricks develops technologies for interrogating high-level cell phenotypes, using high throughput image-based assays. He is also an expert on the malaria parasite and the development of robotic techniques for large-scale experimental biology.

Sanjeev Kumar, PhD


Sanjeev KumarDr. Sanjeev Kumar is a postdoctoral fellow in the Aitchison group. He received his PhD from the University of Groningen, where his research was focused on peroxisome biology. In the Aitchison Lab, his primary research interest is to study the role of the nuclear pore complex in infectious disease.

Song Li

Research associate II

Song Li

Fred Mast, PhD

Senior research scientist

Fred MastDr. Fred Mast is engaged in developing and applying systems cell biology approaches to the understanding of infectious disease. In particular, he is interested in applying and developing new systems-level experimentation to the study of dynamic cellular processes that are fundamental to parasite survival and disease progression. Prior to his current role, Mast was a postdoctoral fellow with the Canadian Institutes of Health Research. His graduate research was completed at the University of Alberta, under the supervision of Professor Richard Rachubinski, a world-renowned expert in cell biology and organelle biogenesis. For his dissertation on peroxisome biology, Mast was awarded the Governor General of Canada’s Academic Gold Medal.

Leslie Miller

Research Associate II

Leslie Miller

Arti Navare, PhD

Research scientist III

Dr. Arti Navare is involved in developing and applying mass spectrometry–based proteomics approaches to map proteome-wide host-pathogen interaction network.

Max Neal, PhD

Senior research scientist

Max NealDr. Max Neal joined the Aitchison Lab in 2016 as a computational biologist. He has 12 years of experience creating and applying simulation models of biological systems at various organizational scales. He has also researched novel approaches for composing complex models from reusable, modular pieces. His efforts in the Aitchison Lab focus on multi-scale modeling of peroxisome biogenesis to better understand how cells regulate peroxisome formation and degradation. He also currently conducts transcriptomic analyses within the contexts of HIV vaccine development and nuclear pore structure/function research.

Paul Olivier, PhD

Senior research scientist

Tiffany Silver-Brace

Grants and contracts administrator

Tiffany Silver-Brace

Jennifer Smith, PhD

Senior scientist

Dr. Jennifer Smith has done research specializing in systems cell biology in the Aitchison Lab for 15 years with a focus on modeling transcriptional regulatory networks. Specifically, she focused on generating dynamic and global gene expression datasets to capture cellular responses, and computationally analyzing these data in various ways to gain biological insights. This work included the development of the indicator cell assay platform (iCAP), a platform for blood based diagnostics that utilizes cultured cells as in vitro biosensors of disease signatures in blood, capitalizing on the natural ability of cells to detect and respond to weak biological signals in noisy environments. The assay involves exposing specifically selected, standardized cells to serum from diseased and normal subjects, and computational analysis of the global transcriptional responses to find reliable disease classifier signatures. She is now CSO at PreCyte, a company focused on developing clinical iCAP assays for neurodegenerative diseases and cancer.